The changing landscape of progressive multifocal leukoencephalopathy

Sachin Kedar, Joseph R. Berger

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare but devastating neurologic disease that affects the immunosuppressed population. The etiologic agent is a polyomavirus, JC virus-a double-stranded DNA virus with a high prevalence of infection globally. PML is believed to occur from reactivation of the latent virus infection caused by immunosuppression. After 1980, a dramatic increase in the incidence and prevalence of PML was attributed to the HIV/AIDS pandemic, with a decline noted after the introduction of highly active antiretroviral treatment (HAART). Newer populations are being added to the risk pool for the development of PML with the introduction of biologic agents that target specific arms of the immune system. Natalizumab and efalizumab seem to have the highest risk for the development of PML, although PML can develop with the other biologic agents. As more patients are treated with these agents, effective risk mitigation strategies are needed to prevent PML.

Original languageEnglish (US)
Pages (from-to)380-386
Number of pages7
JournalCurrent Infectious Disease Reports
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Progressive Multifocal Leukoencephalopathy
Biological Factors
JC Virus
Polyomavirus
DNA Viruses
Pandemics
Virus Diseases
Nervous System Diseases
Immunosuppression
Population
Immune System
Acquired Immunodeficiency Syndrome
HIV
DNA
Incidence
Infection

Keywords

  • AIDS
  • CLL
  • Chronic lymphocytic leukemia
  • Efalizumab
  • HIV
  • JC virus
  • Lymphoma
  • MS
  • Multiple sclerosis
  • Mycophenolate mofetil
  • Natalizumab
  • PML
  • Progressive multifocal leukoencephalopathy
  • Rheumatoid arthritis
  • Rituximab
  • SLE
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

The changing landscape of progressive multifocal leukoencephalopathy. / Kedar, Sachin; Berger, Joseph R.

In: Current Infectious Disease Reports, Vol. 13, No. 4, 01.08.2011, p. 380-386.

Research output: Contribution to journalArticle

@article{2bacf67490444ed2b89e44676d17314f,
title = "The changing landscape of progressive multifocal leukoencephalopathy",
abstract = "Progressive multifocal leukoencephalopathy (PML) is a rare but devastating neurologic disease that affects the immunosuppressed population. The etiologic agent is a polyomavirus, JC virus-a double-stranded DNA virus with a high prevalence of infection globally. PML is believed to occur from reactivation of the latent virus infection caused by immunosuppression. After 1980, a dramatic increase in the incidence and prevalence of PML was attributed to the HIV/AIDS pandemic, with a decline noted after the introduction of highly active antiretroviral treatment (HAART). Newer populations are being added to the risk pool for the development of PML with the introduction of biologic agents that target specific arms of the immune system. Natalizumab and efalizumab seem to have the highest risk for the development of PML, although PML can develop with the other biologic agents. As more patients are treated with these agents, effective risk mitigation strategies are needed to prevent PML.",
keywords = "AIDS, CLL, Chronic lymphocytic leukemia, Efalizumab, HIV, JC virus, Lymphoma, MS, Multiple sclerosis, Mycophenolate mofetil, Natalizumab, PML, Progressive multifocal leukoencephalopathy, Rheumatoid arthritis, Rituximab, SLE, Systemic lupus erythematosus",
author = "Sachin Kedar and Berger, {Joseph R.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s11908-011-0196-6",
language = "English (US)",
volume = "13",
pages = "380--386",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - The changing landscape of progressive multifocal leukoencephalopathy

AU - Kedar, Sachin

AU - Berger, Joseph R.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Progressive multifocal leukoencephalopathy (PML) is a rare but devastating neurologic disease that affects the immunosuppressed population. The etiologic agent is a polyomavirus, JC virus-a double-stranded DNA virus with a high prevalence of infection globally. PML is believed to occur from reactivation of the latent virus infection caused by immunosuppression. After 1980, a dramatic increase in the incidence and prevalence of PML was attributed to the HIV/AIDS pandemic, with a decline noted after the introduction of highly active antiretroviral treatment (HAART). Newer populations are being added to the risk pool for the development of PML with the introduction of biologic agents that target specific arms of the immune system. Natalizumab and efalizumab seem to have the highest risk for the development of PML, although PML can develop with the other biologic agents. As more patients are treated with these agents, effective risk mitigation strategies are needed to prevent PML.

AB - Progressive multifocal leukoencephalopathy (PML) is a rare but devastating neurologic disease that affects the immunosuppressed population. The etiologic agent is a polyomavirus, JC virus-a double-stranded DNA virus with a high prevalence of infection globally. PML is believed to occur from reactivation of the latent virus infection caused by immunosuppression. After 1980, a dramatic increase in the incidence and prevalence of PML was attributed to the HIV/AIDS pandemic, with a decline noted after the introduction of highly active antiretroviral treatment (HAART). Newer populations are being added to the risk pool for the development of PML with the introduction of biologic agents that target specific arms of the immune system. Natalizumab and efalizumab seem to have the highest risk for the development of PML, although PML can develop with the other biologic agents. As more patients are treated with these agents, effective risk mitigation strategies are needed to prevent PML.

KW - AIDS

KW - CLL

KW - Chronic lymphocytic leukemia

KW - Efalizumab

KW - HIV

KW - JC virus

KW - Lymphoma

KW - MS

KW - Multiple sclerosis

KW - Mycophenolate mofetil

KW - Natalizumab

KW - PML

KW - Progressive multifocal leukoencephalopathy

KW - Rheumatoid arthritis

KW - Rituximab

KW - SLE

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=80052609252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052609252&partnerID=8YFLogxK

U2 - 10.1007/s11908-011-0196-6

DO - 10.1007/s11908-011-0196-6

M3 - Article

C2 - 21603877

AN - SCOPUS:80052609252

VL - 13

SP - 380

EP - 386

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 4

ER -